RCUSHealthcare · BiotechnologyThe 13 Wall Street analysts covering Arcus Biosciences, Inc. hold a median 12-month price target of $43 — +72.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 10 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Arcus Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (96): The shares have been drifting up relative to others.
Issuance (25): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RCUS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +72.8% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Sept 2026 | Truist Securities | Reiterates | Buy | $35 → $40 |
| 6 Aug 2026 | Wedbush | Maintains | Outperform | $41 → $43 |
| 6 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $23 → $26 |
| 20 July 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 July 2026 | HC Wainwright & Co. | Maintains | Buy | $32 → $45 |
| 4 June 2026 | LifeSci Capital | Initiates | Outperform | $46 |
| 4 June 2026 | LifeSci Capital | Initiates | Outperform | — |
| 18 May 2026 | Truist Securities | Assumes | Buy | $30 → $35 |
| 11 May 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 7 May 2026 | Goldman Sachs | Maintains | Buy | — |
| 2 Apr 2026 | Wedbush | Maintains | Outperform | — |
| 5 Mar 2026 | Citigroup | Maintains | Buy | — |
| 2 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Mar 2026 | Leerink Partners | Maintains | Outperform | — |
| 12 Feb 2026 | Wells Fargo | Downgrade | Equal-Weight | — |
| 13 Jan 2026 | Goldman Sachs | Upgrade | Buy | — |
| 8 Jan 2026 | Morgan Stanley | Downgrade | Equal-Weight | — |
| 12 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Nov 2025 | B of A Securities | Maintains | Neutral | — |
| 30 Oct 2025 | Goldman Sachs | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RCUS appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Arcus Biosciences, Inc. returned +113.8% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 8% of US stocks
Cheaper than 14% of US stocks
Cheaper than 81% of US stocks
Higher than 3% of US stocks
Higher than 6% of US stocks
Higher than 10% of US stocks
Higher than 30% of US stocks
Higher than 14% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Arcus Biosciences, Inc. has a market value of $3.3B and an enterprise value of $3.2B.
Revenue in the twelve months to 30 June 2026: $117.0M. The latest quarter shrank 74.4% year on year.
Net income over the same four quarters: −$460.0M, a −393.2% net margin.
Diluted earnings per share, trailing twelve months: $−3.90.
Free cash flow in the twelve months to 30 June 2026: −$475.0M.
Trailing P/E: −7.9×; forward P/E: −7.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Arcus Biosciences, Inc. employs 601 people — $195K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Arcus Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Arcus Biosciences announced that its Compensation Committee granted a new employee options to purchase 26,350 shares of common stock at an exercise price of $29.06 per share. This was an employment inducement grant.
Why it matters — RCUS watchers would care because this equity compensation grant indicates a new hire and potential dilution of existing shares.
Arcus Biosciences presented at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the company's remarks made available via Seeking Alpha. The presentation covers the company's participation in the conference.
Why it matters — A RCUS watcher would care because the presentation provides an opportunity to hear management's commentary on the company's pipeline and strategy at an industry conference.
Arcus Biosciences announced that its management team will participate in several upcoming investor conferences in September, including Citi's 2026 Biotech Back to School Conference in New York, where it will take part in a fireside chat. The announcement lists the conference dates and formats for management's participation.
Why it matters — Investor conference appearances give RCUS watchers opportunities to hear management discussing the company's pipeline and strategy with the financial community.
Arcus Biosciences announced that its Compensation Committee granted a new employee options to purchase 2,850 shares of the company's common stock at an exercise price of $28.72 per share, as a new employment inducement grant.
Why it matters — RCUS watchers would note this as a standard employment inducement grant, which reflects routine share-based compensation for a newly hired employee.
Arcus Biosciences reported its second-quarter financial results and, during its earnings call, outlined plans to expand development of its casdatifan cancer program across multiple lines of clear cell renal cell carcinoma. The company also provided updates on its pancreatic cancer and immunology pipelines.
Why it matters — RCUS watchers would care because the company's expansion of the casdatifan program into multiple ccRCC treatment lines signals a key strategic focus for its oncology pipeline.
The 13 Wall Street analysts covering Arcus Biosciences, Inc. have a median 12-month price target of $43, with estimates ranging from $23 to $47. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Arcus Biosciences, Inc., 10 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arcus Biosciences, Inc. 59 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 10 Sept 2026, Arcus Biosciences, Inc. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +72.8% from the last close, and Ticker Nerd's factor model ranks Arcus Biosciences, Inc. 59 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Arcus Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RCUS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $47 over the next 12 months.
Arcus Biosciences, Inc. returned +113.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and combination medicines.
The most recent item we track (Business Wire, 9 Sept 2026): "Arcus Biosciences Announces New Employment Inducement Grants". Arcus Biosciences announced that its Compensation Committee granted a new employee options to purchase 26,350 shares of common stock at an exercise price of $29.06 per share. This was an employment inducement grant.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and combination medicines. The company is building a portfolio of differentiated small molecules and antibodies designed to target key biological pathways involved in tumor growth and immune response. Its current work centers on oncology programs across several solid tumor areas, including lung, gastrointestinal, kidney, and pancreatic cancers. Arcus Biosciences also develops therapies intended to improve how cancer treatments are combined and used in clinical practice, with an emphasis on novel mechanisms such as immuno-oncology and targeted oncology. Headquartered in Hayward, California, Arcus Biosciences operates as a research-driven company working with collaborators to advance investigational medicines through clinical development and toward potential commercialization.
CEO Dr. Terry J. Rosen Ph.D. · 601 employees · United States · https://arcusbio.com
